Evidence map›Paper›PMID 40317559›Full record

ReviewChemistry (Weinheim an der Bergstrasse, Germany)2025

Strategy-Level Prodrug Synthesis.

Paul J Geaneotes, Paul E Floreancig

Abstract readReview
In one paragraph

Review in Chemistry (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Paul J GeaneotesDepartment of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania, 15260, USA.
Paul E FloreancigDepartment of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania, 15260, USA.

Funding

Conditional Control of Drug Function Through α-Boryl Ether OxidationR01GM127153 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DEITERS, ALEXANDER, FLOREANCIG, PAUL E · 2019 to 2022
$1.5M
National Science Foundation CHE-2154551NIGMS NIH HHS R01 GM127153NIGMS NIH HHS R01GM127153
6 · The paper itself

Abstract

Organic synthesis uniquely provides opportunities to access molecules that serve defined purposes. Medicinal chemistry illustrates this attribute well with prodrug design, whereby a drug undergoes a late-stage conversion to a conditionally responsive active medicinal agent (AMA), being a notable example. Prodrugs are becoming increasingly important in medicinal chemistry but common approaches to introduce biologically responsive groups are limited in the chemoselectivity and scope of available functionalization reactions. This Concept article describes strategy-level prodrug synthesis, which is a powerful extension of classical prodrug formation that initiates sequences with the objective of introducing functionality early in a sequence to achieve greater scope, site-selectivity, and chemoselectivity for the incorporation of the biologically responsive group. Examples of functionalization using alkyne hydroamination, Curtius reaction, and alkene metathesis are highlighted along with the use of the prodrugs for biological applications.

Indexed as

ProdrugsAlkenesAlkynesChemistry, PharmaceuticalHumansAlkenesAlkynesProdrugschemoselectivityconditional controlfunctionalizationprodrugsstrategy

Identifiers

PMID40317559
PMCPMC12160975

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.